Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Inflammation 1Endometrial Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 2Standard of Care 2Immune Checkpoint Inhibitors 2Bevacizumab 2venetoclax 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1tipiracil 1spartalizumab 1sotorasib 1selpercatinib 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1montelukast 1malic acid 1icotinib 1gallium maltolate 1encorafenib 1eliglustat 1durvalumab 1daratumumab 1cannabigerol 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × Tablets × Clear all
NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

University of South Florida

Phase EARLY_PHASE1 Not yet recruiting
56 enrolled
CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡